MiRagen Therapeutics completed a $20 million Series B financing. The company will use the money to advance development of its miRNA-based therapeutics pipeline. The financing is being led by Remeditex with participation from miRagen’s existing investor syndicate, which includes Amgen Ventures, Atlas Venture, Boulder Ventures, and Broadview Ventures. “In a short period of time, miRagen [...]
↧